ABLYTX | NEXT-GENERATION TARGETED PROTEIN DEGRADATION
A New Approach to Removing Disease-Driving Membrane Proteins
Introducing SHEDTACs™ — Sheddase-Targeting Chimeras
Ablytx is developing a new class of bispecific antibodies designed to remove disease-driving membrane proteins by harnessing the cell’s own surface proteases.
Rather than relying on proteasomal or lysosomal degradation, SHEDTACs bring target membrane proteins into proximity with naturally occurring cell-surface sheddases — enabling rapid, targeted proteolysis directly at the cell surface.
A New Way to Target the Cell Surface
SHEDTACs harness endogenous cell-surface proteases to catalyze targeted membrane protein proteolysis — without relying on proteasomal or lysosomal degradation.
The result is a direct, programmable approach to removing membrane proteins that may be difficult to address through traditional protein-degradation pathways.
From Platform Concept to In Vivo Efficacy
SHEDTACs are Safe & induce Dose-Dependent Ectodomain shedding in vivo
SHEDTACS show dose-dependent shedding in vivo
• No acute toxicity observed in treated animals
• Soluble biomarker validates MOA in vivo andenables real-time PK/PD measurements
SHEDTACs Restrict Melanoma Growth In Vivo
SHEDTACs restrict tumor growth in a therapy-resistant melanoma model
• SHEDTACs are safe
○ No adverse effects observed in vivo
• SHEDTACs are highly effective
○ Robust tumor restriction in vivo
○ SHEDTACs outperform standard-of-care checkpoint blockade
One Platform. Multiple Therapeutic Opportunities.
SHEDTACs are designed as a modular platform, enabling different membrane targets to be paired with cell-surface proteases across a broad range of disease biology.
LEAD ONCOLOGY ASSET
ONCOLOGY
LAG3
Lead SHEDTAC program targeting checkpoint biology in therapy-resistant cancers.
INFLAMMATION
TNFR1
Platform proof-of-concept program exploring targeted shedding in inflammatory disease.
CNS
APP
Platform proof-of-concept targeting Amyloid Precursor Protein.
AUTOIMMUNITY
Discovery Program
Identification and validation of novel protease-target pairs.
HEMATOLOGY
Discovery Program
Identification and validation of novel protease-target pairs.
A tunable platform with the potential to expand across diverse membrane targets and therapeutic areas.
Advancing SHEDTACs Toward the Clinic
Ablytx is raising $3 million to de-risk its lead oncology asset
And advance two inflammation/autoimmune programs through in vivo proof-of-concept.
01 — LEAD ONCOLOGY ASSET
Advance and de-risk the lead SHEDTAC oncology program.
02 — PLATFORM EXPANSION
Advance two inflammation/autoimmune programs through in vivo proof-of-concept.
03 — VALUE CREATION
Build the preclinical data package needed to support the next stage of development and strategic partnering.
Investment Opportunity
Building value through focused preclinical development
Ablytx is advancing a differentiated approach to targeted protein degradation with demonstrated in vivo activity and a modular platform designed for expansion across multiple therapeutic areas.
VALIDATED PLATFORM
In vivo evidence of target shedding and therapeutic activity.
FOCUSED DEVELOPMENT
Capital directed toward de-risking the lead oncology asset and advancing additional programs.
EXPANSION POTENTIAL
A modular technology designed to address diverse membrane targets across multiple disease areas.
Connect With AblytxInterested in learning more about SHEDTAC technology, Ablytx’s development programs, or the current investment opportunity?
REQUEST THE NON-CONFIDENTIAL DECK BELOW
